• 四川大學(xué)華西醫(yī)院血液科，四川成都 610041;

目的：探討蛋白酶體抑制劑——硼替佐米對(duì)初治多發(fā)性骨髓瘤的療效及對(duì)移植造血干細(xì)胞采集的影響。方法：對(duì)一例初發(fā)的中年男性多發(fā)性骨髓瘤患者使用硼替佐米+地塞米松+反應(yīng)停（VTD）的方案進(jìn)行化療，獲得緩解后采集外周血造血干細(xì)胞。結(jié)果：應(yīng)用以硼替佐米為基礎(chǔ)的方案治療3個(gè)療程后，患者即獲得完全緩解；完成4個(gè)療程化療后成功采集足夠數(shù)量的外周血造血干細(xì)胞；完成6個(gè)療程化療后，進(jìn)入維持治療，至今已完全緩解17個(gè)月。治療過(guò)程中除惡心、嘔吐外無(wú)其他明顯不良反應(yīng)。結(jié)論：硼替佐米用于初治多發(fā)性骨髓瘤有良好的治療效果，不良反應(yīng)少，不影響造血干細(xì)胞采集。

引用本文： 劉志剛,牛挺,劉葳,朱煥玲,賈永前,鄧承祺,劉霆. 硼替佐米治療初治多發(fā)性骨髓瘤成功病例報(bào)告. 華西醫(yī)學(xué), 2008, 23(1): 73-74. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《華西醫(yī)學(xué)》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. [11]Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or High-Dose Dexa methasone for Relapsed Multiple Myeloma[J].N Engl J Med,2005,352:2487-98.
2. [12]Richardson PG,Chanan-Khan A,Schlossman R,et al.A multicenter phase Ⅱ trial of bortezomib in Patients with previously untreated multiple myeloma:efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy[J].Blood,2005,106:2548.
3. [13]Wang LM,Weber DM,Delasalle KB,et al.VTD (Velcade,Thelidomide,Dexamethaso me) as primary therapy for newly-diagnosed multiple myeloma[J].Blood,2004,104:210.
4. [14]Harousseau JL,Attal M,Leleu X,et al.Bortezomib(Velcade)plus decamethas one as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:preliminary results of an IFM phase II study[J].Blood,2004,104:1490.
5. [15]Peles S,Fisher NM,Devine SM,et al.Bortezomib(velcade)when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV)[J].Blood,2005,106:3237.
6. [16]Geoffrey LU,Fisher NM,Devine SM,et al.Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma[J].Blood,2005,106:2926.
7. Adams J.The proteasome:structure,function,and role in the cell[J].Cancer Treat Rev,2003,29(suppl 1)3-9.
8. Kyle RA,Rajkumar SV.Drug therapy of multiple myeloma[J].N Engl J Med,2004,351:1860-73.
9. Voorhees PM,Dees EC,O’Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9:6316-25.
10. Richardson PG,Mitsiades C.Bortezomib:proteasome inhibition as an effective anticancer therapy[J].Annu Rev Med,2006,57:33-47.
11. O’Connor OA.Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell ly mphoma[J].Clin Lymphoma Myeloma,2005,6(3):191-9.
12. Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyelomaactivity of proteasome inhibitor PS-341[J].Blood,2003,101:1530.
13. Roccaro AM,Hideshima T,Raje N,et al.Bortezomib targets multiple myeloma endothelial cells[J].Blood,2004,104:4903.
14. Heider U,Kaiser M,Muller C,et al.Treatment of bortezomib increases osteoblast function in patients with multiple myeloma[J].Blood,2005,106:3457.
15. Richardson PG,Barlogie B,Berenson J,et al.A phase 2study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348:2609-17.
16. Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progressionin patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation[J].Br J Haematol,1998,102:1115-23.
  1. 1. [11]Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or High-Dose Dexa methasone for Relapsed Multiple Myeloma[J].N Engl J Med,2005,352:2487-98.
  2. 2. [12]Richardson PG,Chanan-Khan A,Schlossman R,et al.A multicenter phase Ⅱ trial of bortezomib in Patients with previously untreated multiple myeloma:efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy[J].Blood,2005,106:2548.
  3. 3. [13]Wang LM,Weber DM,Delasalle KB,et al.VTD (Velcade,Thelidomide,Dexamethaso me) as primary therapy for newly-diagnosed multiple myeloma[J].Blood,2004,104:210.
  4. 4. [14]Harousseau JL,Attal M,Leleu X,et al.Bortezomib(Velcade)plus decamethas one as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:preliminary results of an IFM phase II study[J].Blood,2004,104:1490.
  5. 5. [15]Peles S,Fisher NM,Devine SM,et al.Bortezomib(velcade)when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV)[J].Blood,2005,106:3237.
  6. 6. [16]Geoffrey LU,Fisher NM,Devine SM,et al.Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma[J].Blood,2005,106:2926.
  7. 7. Adams J.The proteasome:structure,function,and role in the cell[J].Cancer Treat Rev,2003,29(suppl 1)3-9.
  8. 8. Kyle RA,Rajkumar SV.Drug therapy of multiple myeloma[J].N Engl J Med,2004,351:1860-73.
  9. 9. Voorhees PM,Dees EC,O’Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9:6316-25.
  10. 10. Richardson PG,Mitsiades C.Bortezomib:proteasome inhibition as an effective anticancer therapy[J].Annu Rev Med,2006,57:33-47.
  11. 11. O’Connor OA.Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell ly mphoma[J].Clin Lymphoma Myeloma,2005,6(3):191-9.
  12. 12. Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyelomaactivity of proteasome inhibitor PS-341[J].Blood,2003,101:1530.
  13. 13. Roccaro AM,Hideshima T,Raje N,et al.Bortezomib targets multiple myeloma endothelial cells[J].Blood,2004,104:4903.
  14. 14. Heider U,Kaiser M,Muller C,et al.Treatment of bortezomib increases osteoblast function in patients with multiple myeloma[J].Blood,2005,106:3457.
  15. 15. Richardson PG,Barlogie B,Berenson J,et al.A phase 2study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348:2609-17.
  16. 16. Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progressionin patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation[J].Br J Haematol,1998,102:1115-23.